Exelixis
EXEL
#2109
Rank
S$9.81 B
Marketcap
$34.41
Share price
-1.53%
Change (1 day)
16.82%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total debt

Total debt on the balance sheet as of June 2024 : S$0.25 B

According to Exelixis's latest financial reports the company's total debt is S$0.25 B. A companyโ€™s total debt is the sum of all current and non-current debts.

Exelixis - Total debt on balance sheet (from 2000 to 2024)

Total debt by year

Year Total debt Change
2023-12-31S$0.25 B-1.6%
2022-12-31S$0.25 B268.7%
2021-12-31S$69.14 M6.55%
2020-12-31S$64.89 M0.52%
2019-12-31S$64.56 M217.73%
2018-12-31S$20.31 M1.7%
2017-12-31S$19.97 M-92.7%
2016-12-31S$0.27 B-53.74%
2015-12-31S$0.59 B25.46%
2014-12-31S$0.47 B7.19%
2013-12-31S$0.44 B7.1%
2012-12-31S$0.41 B74.77%
2011-12-31S$0.23 B-12.5%
2010-12-31S$0.26 B140.1%
2009-12-31S$0.11 B-33.88%
2008-12-31S$0.16 B-3.68%
2007-12-31S$0.17 B-5.81%
2006-12-31S$0.18 B-24.73%
2005-12-31S$0.24 B14.06%
2004-12-31S$0.21 B14.93%
2003-12-31S$0.18 B47.37%
2002-12-31S$0.12 B41.59%
2001-12-31S$90.6 M249.68%
2000-12-31S$25.91 M17.01%
1999-12-31S$22.14 M

Total debt for similar companies or competitors

Company Total debt differencediff. Country
S$27.92 B 10,725.89%๐Ÿ‡ฌ๐Ÿ‡ง UK
S$33.16 B 12,757.84%๐Ÿ‡ซ๐Ÿ‡ท France
S$49.22 B 18,983.21%๐Ÿ‡บ๐Ÿ‡ธ USA
S$70.34 B 27,172.41%๐Ÿ‡บ๐Ÿ‡ธ USA
S$81.59 B 31,536.17%๐Ÿ‡บ๐Ÿ‡ธ USA
S$54.04 B 20,853.25%๐Ÿ‡บ๐Ÿ‡ธ USA
S$89.45 B 34,582.38%๐Ÿ‡บ๐Ÿ‡ธ USA
S$4.63 M-98.20%๐Ÿ‡บ๐Ÿ‡ธ USA
S$50.38 M-80.47%๐Ÿ‡บ๐Ÿ‡ธ USA